ArticleInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2017
Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future.
Article in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Meta-analysis of the diagnostic value ofFrontiers in oncology · 2022Pooled it
- Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer.Frontiers in immunology · 2019Trial
- Missing moments and being a burden: the lived experience of fear of cancer recurrence among older rural Australian women.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Article
- Genetic and Molecular Determinants of Immunotherapy Response in Recurrent Ovarian Cancer.Anti-cancer agents in medicinal chemistry · 2026Review
- Red blood cell-hitchhiking fluorescent probe to promote intraoperative diagnosis of human ovarian tumor.Science advances · 2025Article
- Development of a PANoptosis-Related Pathomics Prognostic Model in Ovarian Cancer: A Multi-Omics Study.Journal of cellular and molecular medicine · 2025Article
- RECQL1 as a potential therapeutic target for PARP inhibitor-resistant ovarian cancer.Scientific reports · 2025Article
- UBD-mediated glycolytic reprogramming promotes M2 macrophage polarization in ovarian cancer immune evasion.Journal of cell communication and signaling · 2025Article
- Myeloid activation clears ascites and reveals IL27-dependent regression of metastatic ovarian cancer.The Journal of experimental medicine · 2024Article
- Article
- A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers.Oncology and therapy · 2024Review
- Interplay between altered metabolism and DNA damage and repair in ovarian cancer.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024Review
- The role of lncRNA NEAT1 in human cancer chemoresistance.Cancer cell international · 2024Review
- Intraperitoneal activation of myeloid cells clears ascites and reveals IL27-dependent regression of metastatic ovarian cancer.bioRxiv : the preprint server for biology · 2024Article
- Research progress on the psychological burden and intervention measures in cancer patients.Frontiers in psychiatry · 2024Review
- Novel Therapeutics in Ovarian Cancer: Expanding the Toolbox.Current oncology (Toronto, Ont.) · 2023Review
- Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.Cancer letters · 2023Article
- Triptolide inhibits epithelial ovarian tumor growth by blocking the hedgehog/Gli pathway.Aging · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOvarian cancer recurs in most patients, with a 5-year survival rate less than 30%. Quality of life is an increasingly important issue in patients with cancer, but there are limited data in women with recurrent ovarian cancer in this regard. MATERIALS AND
methodsWe used an ad hoc questionnaire to compare changes in health perceptions, burden of disease, and expectations for the future quality of life in women with and without recurrence of ovarian cancer. A total of 173 women were included, 116 with relapse and 57 without, undergoing follow-up in a routine clinical setting.
resultsSubstantial differences were seen in self-assessed health status between women with and without recurrence; 33.6% and 82.4% of women with and without recurrence rated their health as good to excellent, respectively. More patients with recurrence of disease reported limitations in moderate activity than those without. Furthermore, 79.0% of women without recurrence reported that pain did not affect or only slightly affected daily activities, compared with 28.2% with recurrence. Most women with recurrence (59.5%) reported that they were able to do less than they wanted to because of their emotional status compared with only 15.8% of women without recurrence. In addition, 66.4% of women with recurrence referred that they had problems concentrating at work and home versus 26.3% of women without recurrence.
conclusionsFrom this survey, it is clear that relapse of disease has a negative psychological and physical impact, highlighting the importance of time without recurrence and the need for effective treatment in the long term.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.